Ozempic & GLP-1 Lawsuit
GLP-1 receptor agonists — including Ozempic, Wegovy, Rybelsus, and Saxenda from Novo Nordisk, and Mounjaro, Zepbound, and Trulicity from Eli Lilly — have transformed diabetes care and weight loss, with tens of millions of prescriptions written. They work in part by dramatically slowing how quickly the stomach empties. Lawsuits allege that for some patients, that mechanism went much further than the labels disclosed.
Why Are Ozempic and GLP-1 Lawsuits Being Filed?
Plaintiffs allege the manufacturers failed to adequately warn about severe and sometimes long-lasting gastrointestinal injuries — most commonly gastroparesis (stomach paralysis), along with ileus, intestinal obstruction, intractable vomiting, and gallbladder complications. A second wave of litigation involves NAION (non-arteritic anterior ischemic optic neuropathy), a form of sudden, often permanent vision loss; a 2024 JAMA Ophthalmology study reported a statistical association between semaglutide use and NAION, and subsequent research has added to that record. The manufacturers deny the allegations and maintain the drugs are safe when used as directed.
Two MDLs: Where the Litigation Stands
Gastrointestinal injury claims are consolidated in MDL 3094 in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston, with roughly 3,800 cases pending as of mid-2026 and expert (Daubert) briefing underway. An August 2025 ruling requires gastroparesis plaintiffs to support their claims with objective testing such as a gastric emptying study, which now shapes case screening. In December 2025, vision loss claims were consolidated into a separate MDL 3163, also before Judge Marston, which held a Science Day in June 2026 and is growing alongside parallel state court proceedings in New Jersey and Indiana. No trials have been held and no settlements announced in either MDL.
Injuries in the GLP-1 Litigation
Gastroparesis with persistent vomiting and hospitalization, ileus and bowel obstruction, gallbladder injury, and NAION vision loss. Documented, objective findings — a gastric emptying study for gastroparesis, an ophthalmologist’s NAION diagnosis for vision loss — are what distinguish strong claims.
Who May Qualify?
You may qualify for a free case review if you took a brand-name GLP-1 medication and were diagnosed with gastroparesis (ideally confirmed by a gastric emptying study), suffered a bowel obstruction or ileus requiring treatment, or experienced sudden vision loss diagnosed as NAION. Prescription records and the objective diagnostic workup are the core evidence.
Important: Do not stop taking a prescribed GLP-1 medication without talking to your doctor first, especially if you take it for diabetes.